BioPharma Dive1 min read
saveOne of Europe’s leading VCs banks a €725M ‘crossover’ fund
Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.
comments(0)
5-min edit window · permanent after that